All In Biotech

Drug Trial Radar · NCT00378508

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Aug 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

63

Actual

Start

Sep 2006

Primary completion

Aug 2011

Study completion Aug 2013

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation
First posted
Sep 20, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized placebo controlled study to test whether a single 14 course of treatment with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss of insulin secretory capacity in individuals with Type 1 diabetes of 4 - 12 months duration since diagnosis.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • mAb hOKT3gamma1(Ala-Ala), TeplizumabDrug

    This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.

  • Placebo ArmDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at 12 MonthsTime frame: At month 12 post-treatment
  2. C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at BaselineTime frame: At Baseline (before treatment)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California at San Francisco

    San Francisco, California

  • Barbara Davis Diabetes Center

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.